52.26
Schlusskurs vom Vortag:
$51.27
Offen:
$51.71
24-Stunden-Volumen:
225.26K
Relative Volume:
0.81
Marktkapitalisierung:
$2.12B
Einnahmen:
$982.01M
Nettoeinkommen (Verlust:
$14.80M
KGV:
141.24
EPS:
0.37
Netto-Cashflow:
$37.02M
1W Leistung:
-1.53%
1M Leistung:
+29.16%
6M Leistung:
+68.80%
1J Leistung:
+107.46%
Phibro Animal Health Corp Stock (PAHC) Company Profile
Firmenname
Phibro Animal Health Corp
Sektor
Telefon
201-329-7300
Adresse
GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ
Compare PAHC vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PAHC
Phibro Animal Health Corp
|
52.26 | 2.08B | 982.01M | 14.80M | 37.02M | 0.37 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Phibro Animal Health Corp Stock (PAHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-06-16 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2024-09-10 | Eingeleitet | JP Morgan | Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2022-12-21 | Eingeleitet | ROTH Capital | Buy |
| 2022-07-25 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-10 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-07-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-08-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2020-02-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-01-28 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-08-29 | Bestätigt | BofA/Merrill | Underperform |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-09 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2017-08-23 | Fortgesetzt | BofA/Merrill | Underperform |
| 2017-06-02 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-12-15 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-11-11 | Herabstufung | Macquarie | Neutral → Underperform |
| 2016-11-10 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2016-04-11 | Bestätigt | Guggenheim | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2016-01-15 | Herabstufung | Barclays | Overweight → Underweight |
| 2015-09-30 | Eingeleitet | Gabelli & Co | Buy |
| 2015-04-24 | Bestätigt | Barclays | Overweight |
| 2015-04-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2014-05-06 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Phibro Animal Health Corp Aktie (PAHC) Neueste Nachrichten
Will Phibro Animal Health Corporation benefit from sector rotation2025 Price Momentum & Trade Opportunity Analysis - mfd.ru
Will Phibro Animal Health Corporation benefit from AI trends2025 Volume Leaders & Reliable Price Breakout Signals - baoquankhu1.vn
Aug Rallies: Is Phibro Animal Health Corporation gaining market shareJuly 2025 Review & Risk Managed Trade Strategies - baoquankhu1.vn
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock - Yahoo Finance
Why Phibro (PAHC) International Revenue Trends Deserve Your Attention - Yahoo Finance
Penserra Capital Management LLC Makes New $519,000 Investment in Phibro Animal Health Corporation $PAHC - Defense World
Phibro Animal Health Signals Strong Momentum in Earnings - TipRanks
Phibro Animal Health (NASDAQ:PAHC) Is Due To Pay A Dividend Of $0.12 - Yahoo Finance
Phibro Animal Health Corporation (NASDAQ:PAHC) Q2 2026 Earnings Call Transcript - Insider Monkey
3 Reasons Growth Investors Will Love Phibro (PAHC) - Yahoo Finance
Phibro Animal Health (PAHC) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Phibro Animal Health Corporation $PAHC Shares Sold by Ranger Investment Management L.P. - MarketBeat
Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Phibro Animal Health Q2 Earnings Call Highlights - Yahoo Finance
Phibro Animal Health (PAHC) Margin Rebound And EPS Surge Test Cautious Growth Narratives - simplywall.st
Phibro Animal Health (PAHC) Is Up 25.3% After Issuing 2026 Sales And EPS GuidanceWhat's Changed - Yahoo Finance
Phibro Animal Health Corp (PAHC) Q2 2026 Earnings Call Highlight - GuruFocus
Phibro Animal Health Corp (PAHC) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Phibro Animal Health stock hits 52-week high at $46.95 - Investing.com
Phibro Animal Health now targets up to 85% profit growth in 2026 - Stock Titan
Hershey Posts Upbeat Q4 Earnings, Joins FormFactor, ITT, Cardinal Health And Other Big Stocks Moving Higher On Thursday - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Phibro Q2 2026 presentation: Animal Health drives 21% revenue growth, guidance raised - Investing.com
Earnings call transcript: Phibro Animal Health beats Q2 2026 forecasts, stock surges - Investing.com
Chart Watch: What is the long term forecast for Phibro Animal Health Corporation stockQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Phibro Animal Health Fiscal Q2 Adjusted Earnings, Sales Rise; Lifts FY26 Outlook; Shares Soar Premarket - marketscreener.com
Decoding Phibro Animal Health Corp (PAHC): A Strategic SWOT Insi - GuruFocus
Compared to Estimates, Phibro (PAHC) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Phibro Animal Health (NASDAQ:PAHC) Misses Q2 CY2026 Revenue Estimates, But Stock Soars 5.5% - Finviz
Phibro: Overview of Second Quarter Financial Results - Bitget
Phibro Animal Health (PAHC) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Phibro Animal Health (PAHC) Exceeds Revenue Forecasts, Raises An - GuruFocus
Phibro: Fiscal Q2 Earnings Snapshot - marketscreener.com
Phibro Animal Health Corporation Reports Strong Q2 Results and Updates Financial Guidance - TradingView
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance - Yahoo Finance
Phibro Animal Health declares $0.12 quarterly dividend - Investing.com
Animal health company to pay $0.12 per share dividend in March - Stock Titan
Earnings Preview For Phibro Animal Health - Benzinga
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions - TradingView
Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 6,693 Shares of Stock - MarketBeat
Phibro Animal Health (NASDAQ:PAHC) CEO Sells $271,692.64 in Stock - MarketBeat
A Look At Phibro Animal Health (PAHC) Valuation After Strong 1 Year Returns And Recent Pullback - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Finviz
Hussman Strategic Advisors Inc. Sells 42,000 Shares of Phibro Animal Health Corporation $PAHC - MarketBeat
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results - Yahoo Finance
Reasons to Retain Baxter International Stock in Your Portfolio Now - Finviz
PAHC Q2 Earnings Preview: Animal Health Momentum Likely to Aid Results - Yahoo Finance
What makes Prothena Corporation plc stock price move sharply - baoquankhu1.vn
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now? - Yahoo Finance
Lobbying Update: $30,000 of PHIBRO ANIMAL HEALTH CORPORATION lobbying was just disclosed - Quiver Quantitative
Finanzdaten der Phibro Animal Health Corp-Aktie (PAHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phibro Animal Health Corp-Aktie (PAHC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BENDHEIM JACK | President and CEO |
Feb 11 '26 |
Sale |
51.62 |
14,184 |
732,186 |
50,760 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):